Loading
GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding.
CIViC holds 9 clinical evidence items and 0 assertions across 5 variants, naming Trametinib, Mirdametinib, Selumetinib and Cabozantinib and others. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.83, literature 0.90, genetic association 0.00, somatic mutation 0.90, animal model 0.63). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Melanoma, Uveal Melanoma. In OnCo, 1 product record names it (Darovasertib).
In plain words · GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.
GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades.
No product in this corpus aims at GNA11 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: 1 of 1 medicines aimed at it name a mutant, fusion, exon or hotspot in their mechanism (Darovasertib), an alteration absent from normal cells. HPA GNA11: RNA low tissue specificity; no normal tissue stained high; highest cancer staining head and neck cancer (1 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 4 of scripts/fetch-target-specificity.ts.)
Sources: ClinicalTrials.gov: trials of Darovasertib; Human Protein Atlas GNA11 tissue; Open Targets ENSG00000088256 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Jiang et al, Proc. Natl. Acad. Sci. U.S.A, 1991, "Guanine nucleotide-binding regulatory proteins in retinal pigment epithelial cells". Source.
Sources: HGNC HGNC:4379 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29992 (protein name, function text, keywords and locations (REST API)); CIViC gene GNA11 (9 evidence items, 0 assertions, 5 variants; diseases: Uveal Melanoma, Cancer, Congenital Hemangioma (GraphQL API, CC0)); Open Targets ENSG00000088256 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: melanoma 0.71, skin cancer 0.62, ocular melanoma 0.63, lung cancer 0.51 (GraphQL API, CC0)); IntOGen GNA11 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal. Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins. Signalling is mediated via phospholipase C-beta-dependent inositol lipid hydrolysis for signal propagation: activates phospholipase C-beta: following GPCR activation, GNA11 activates PLC-beta (PLCB1, PLCB2, PLCB3 or PLCB4), leading to production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Location: Cell membrane; Cytoplasm (UniProt). Locus 19p13.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Appendix, Caudate, Cerebellum, Colon, Endometrium, Gallbladder and more.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GNA11" OR ABSTRACT:"GNA11" OR TITLE:"G protein subunit alpha 11" OR ABSTRACT:"G protein subunit alpha 11" OR TITLE:"Guanine nucleotide-binding protein subunit alpha-11" OR ABSTRACT:"Guanine nucleotide-binding protein subunit alpha-11" OR TITLE:"FBH2" OR ABSTRACT:"FBH2" OR TITLE:"FHH2" OR ABSTRACT:"FHH2" OR TITLE:"HHC2" OR ABSTRACT:"HHC2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNA11, not a curated reading list.
Shares Darovasertib, Uveal melanoma, Skin cancer (all types), CIViC.
Shares Uveal melanoma, CIViC, IntOGen, Lung cancer (all types).
Shares Darovasertib, Uveal melanoma, Melanoma.
Shares Darovasertib, Uveal melanoma.
Shares Darovasertib, Uveal melanoma.
Shares Uveal melanoma, CIViC, IntOGen.
Shares Uveal melanoma, CIViC, Melanoma, Open Targets Platform.
Shares Darovasertib, Uveal melanoma, Melanoma.